RxDoctor Payments Data

Inocencia Carrano, MD

Spinal Cord Injury Medicine · Middletown, NYNPI 1770580862

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 365 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 50 manufacturers, the largest accounting for just 20.9% — the pattern of someone who eats at a lot of different presentations.

$7,091in general payments, 2019–2025

Across 365 payments — averaging $19.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$1K
  • AbbVie$1K
  • Organogenesis Inc.$832
  • Scilex Pharmaceuticals Inc.$553
  • Bsn Medical Inc$240
  • Reprise Biomedical, Inc.$215
  • plus $3K from 44 others

What the payments were for

  • Food & beverage$7,091100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few spinal cord injury medicine providers in New Yorkto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$250,739
Medicare patients
368
Services billed
4,713

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.100$276,820
Nurtec OdtRimegepant Sulfate19$17,288
NuedextaDextromethorphan Hbr/Quinidine11$16,849
Baclofen350$8,527
MyrbetriqMirabegron15$7,978
Gabapentin395$5,124
Clobetasol Propionate71$4,969
Duloxetine Hcl213$4,345
Oxycodone Hcl172$4,190
Pregabalin116$3,784
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen61$2,746
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen135$2,248
Fentanyl39$2,005
Methenamine Hippurate25$1,376
Lidocaine15$1,219

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$1,483$276,820100 claims
PfizerNurtec Odt$83$17,28819 claims
Avanir Pharmaceuticals, Inc.Nuedexta$76$16,84911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few spinal cord injury medicine providers in New Yorkon file to place this against a meaningful peer group, so we don't.

Other spinal cord injury medicine in Middletown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →